About 200 reports

You can easily book an appointment with one online.

  • Cell Therapy
  • World
  • Forecast
  • Merck & Co., Inc.
  • Sanofi S.A.

AT THAT TIME, THE US HAD AUTHORIZED THE SALE OF ONLY ONE BIOSIMILAR, NAMELY Source: Roots Analysis (Global Biosimilars Market, 2015-2025) ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## US Europe Japan China India Brazil Mexico Argentina Korea Marketed Pr

  • Cell Therapy
  • North America
  • United States
  • World
  • Biologics, Inc.

SR ONE ##.

  • Cell Therapy
  • China
  • Celgene Corporation
  • Juno Therapeutics Inc.
  • Novartis AG

Hoffmann-La Roche Ltd. ## ## ## ## ## ## ## ## Amgen Inc. ## ## ## ## ## ## ## ## AbbVie Inc. ## ## ## ## ## ## ## ## Source: GlobalData' s Pharma eTrack Clinical Trials Database (*)Trials are taken for a time period of 1995 - 2015 2015 trials are taken as of Augu

  • Cell Therapy
  • World
  • AbbVie Inc.
  • Bristol-Myers Squibb Company
  • Seattle Genetics, Inc.

FILGRASTIM AS AN ALTERNATIVE TO DONOR LEUKOCYTE INFUSION FOR RELAPSE AFTER ALLOGENEIC STEM-CELL TRANSPLANTATION.

  • Cell Therapy
  • Athersys, Inc.
  • Fresenius Group
  • GlobalData's company
  • Soligenix, Inc.
  • undisclosed chemotherapy, topotecan hydrochloride, melphalan, filgrastim, busulfan and autologous hematopoietic stem cells alone or in combination have the highest number of nonseminomatous testicular cancer ongoing clinical trials.

Nonseminomatous Testicular Cancer Global Clinical Trials Review, H1, 2018 Summary GlobalData’s clinical trial report, “Nonseminomatous Testicular Cancer Global Clinical Trials Review, H1, 2018" provides an overview of Nonseminomatous Testicular Cancer clinical trials scenario.This report provides...

  • Cell Therapy
  • Chemotherapy
  • Therapy
  • World
  • Product Initiative
  • MARKET LEADERS IN CELL CULTURE, 2014
  • CURRENT AND FUTURE TRENDS

s Neupogen (filgrastim), which was originally licensed in 1991.

  • Cell Therapy
  • Affymetrix, Inc.
  • Life Technologies Corporation
  • Sigma-Aldrich
  • Thermo Fisher Scientific, Inc.

The prominent features of this report are - ##.

  • Cell Therapy
  • HIV AIDS
  • Lymphoma
  • Monoclonal Antibody
  • F. Hoffmann-La Roche Ltd.
  • Target
  • Clinical Trial profile. 148 Trial Title

Leukocyte Disorders (White Blood Cell Disorders) Global Clinical Trials Review, H2, 2017 Summary GlobalData’s clinical trial report, “Leukocyte Disorders (White Blood Cell Disorders) Global Clinical Trials Review, H2, 2017" provides an overview of Leukocyte Disorders (White Blood Cell Disorders)...

  • Blood Disease
  • Cell Therapy
  • Chemotherapy
  • Clinical Trial
  • World

The prominent features of this report are - ##.

  • Cell Therapy
  • HIV AIDS
  • Lymphoma
  • World
  • Product Initiative
  • Clinical Trial profile. 172 Trial Title
  • Clinical Trial profile. 283 Trial Title

The prominent features of this report are - ##.

  • Cell Therapy
  • Leukemia
  • Monoclonal Antibody
  • United States
  • World
  • Therapy Area Indication(s)

Hematological Tumor Global Clinical Trials Review, H2, 2017 Summary GlobalData’s clinical trial report, “Hematological Tumor Global Clinical Trials Review, H2, 2017" provides an overview of Hematological Tumor clinical trials scenario. This report provides top line data relating to the clinical trials on Hematological...

  • Cancer
  • Cell Therapy
  • Clinical Trial
  • World
  • Product Initiative

Monday, April ##, ##:##-##:## p. m.

  • Cancer
  • Cell Therapy
  • Clinical Trial
  • World
  • Product Initiative

## ## ## ## ## ## ## ## Jazz Pharmaceuticals Plc ## ## ## ## ## ## ## ## Takeda Pharmaceutical Co Ltd ## ## ## ## ## ## ## ## Sanofi ## ## ## ## ## ## ## ## Pfizer Inc ## ## ## ## ## ## ## ## Bristol-Myers Squibb Co ## ## ## ## ## ## ## ## AbbVie Inc ## ## ## ## ##

  • Cancer
  • Cell Therapy
  • Clinical Trial
  • World
  • Product Initiative
  • Clinical Trial profile. 729 Trial Title
  • Clinical Trial profile. 626 Trial Title

The prominent features of this report are - ##.

  • Cell Therapy
  • Clinical Trial
  • Oncology
  • World
  • Celgene Corporation
  • Clinical Trial profile. 375 Trial Title
  • Clinical Trial profile. 294 Trial Title

Hoffmann-La Roche Ltd ## ## ## ## ## ## ## ## Progenics Pharmaceuticals Inc ## ## ## ## ## ## ## ## United Therapeutics Corp ## ## ## ## ## ## ## ## Novartis AG ## ## ## ## ## ## ## ## APEIRON Biologics AG ## ## ## ## ## ## ## ## Pfizer Inc ## ## ## ## ## ## ## ## Y-mAbs Therapeutics Inc ##

  • Cell Therapy
  • Clinical Trial
  • Oncology
  • World
  • Progenics Pharmaceuticals, Inc.
  • Clinical Trial profile. 51 Trial Title
  • Clinical Trial profile. 53 Trial Title

## ## ## ## Merck & Co Inc ## ## ## ## ## Groupe Francophone des Myelodysplasies ## ## ## ## ## Daiichi Sankyo Co Ltd ## ## ## ## ## CTI BioPharma Corp ## ## ## ## ## Celerion Inc ## ## ## ## ## Bristol-Myers Squibb C

  • Cell Therapy
  • Therapy
  • World
  • Product Initiative
  • Celgene Corporation
  • R&D Progress

NA : Not Available Source: Global Markets Direct DRUGS TO INHIBIT SIRT## FOR ISCHEMIC STROKE AND MYOCARDIAL INFARCTION - DRUG PROFILE DS-## - DRUG PROFILE EP-## - DRUG PROFILE EPGN-## - DRUG PROFILE EPOETIN ALFA - DRUG PROFILE FILGRASTIM - DRUG PROFILE Drug Name Company/ Institute

  • Cell Therapy
  • Neurological Disorder
  • United States
  • Company
  • Product Initiative
  • Clinical Trial profile. 13 Trial Title

## ## Prothena Corp Plc ## ## ## ## Johnson & Johnson ## ## ## ## Takeda Pharmaceutical Co Ltd ## ## ## ## TheraPharm Deutschland GmbH ## ## ## ## Spectrum Pharmaceuticals Inc ## ## ## ## GlaxoSmithKline Plc ## ## ##

  • Cell Therapy
  • Endocrine Disease
  • Therapy
  • World
  • Product Initiative

The prominent features of this report are - ##.

  • Cell Therapy
  • Clinical Trial
  • Leukemia
  • Therapy
  • Novartis AG
  • Clinical Trial profile. 779 Trial Title
  • CLINICAL TRIAL PROFILE. 971 TRIAL TITLE

The prominent features of this report are - ##.

  • Cancer
  • Cell Therapy
  • Clinical Trial
  • Ovarian Cancer
  • World
  • Clinical Trial profile. 161 Trial Title
  • 5. All the trials included are unique trials.

## ## ## ## ## ## Germany ## ## ## ## ## ## ## ## Japan ## ## ## ## ## ## ## ## United Kingdom ## ## ## ## ## ## ## ## France ## ## ## ## ## ## ## ## Italy ## ## ## ## ## ## ## ## Canada Source: GlobalData' s Phar

  • Blood Disease
  • Cell Therapy
  • General Medicine And Specialty Medicine
  • World
  • Product Initiative

The prominent features of this report are - ##.

  • Cell Therapy
  • Lymphoma
  • United States
  • World
  • Product Initiative

The prominent features of this report are - ##.

  • Cell Therapy
  • Clinical Trial
  • Oncology
  • Therapy
  • Eli Lilly & Co.
  • Clinical Trial profile. 133 Trial Title
  • Clinical Trial profile. 101 Trial Title

The prominent features of this report are - ##.

  • Blood Disease
  • Cell Therapy
  • Clinical Trial
  • General Medicine And Specialty Medicine
  • World

## ## ## ## ## ## Novartis AG ## ## ## ## ## ## Actinium Pharmaceuticals Inc ## ## ## ## ## ## SymBio Pharmaceuticals Ltd ## ## ## ## ## ## Sanofi ## ## ## ## ## ## Onconova Therapeutics Inc ## ## ## ## ## ## Nohla Therapeutics Inc ## ## ##

  • Blood Disease
  • Cell Therapy
  • Leukemia
  • World
  • Celgene Corporation
  • Clinical Trial profile. 636 Trial Title

Patients were randomized ##:## to receive PVd or Vd.

  • Cell Therapy
  • Clinical Trial
  • Monoclonal Antibody
  • Oncology
  • Celgene Corporation

The prominent features of this report are - ##.

  • Cancer
  • Cell Therapy
  • Therapy
  • World
  • Eli Lilly & Co.

Its biosimilars products comprise PEG-filgrastim, teriparatide, somatropin, filgrastim, platelet-derived growth factor-BB, epidermal growth factor and glucagon.

  • Cell Therapy
  • Chronic Disease
  • United States
  • Product Initiative
  • ViroMed Co., Ltd.

## ## ## Merck & Co Inc ## ## ## ## ## ## AstraZeneca Plc ## ## ## ## ## ## Eli Lilly and Co ## ## ## ## ## ## GlaxoSmithKline Plc ## ## ## ## ## ## Novartis AG ## ## ## ## ## ## Pfizer Inc ## ## ## ## ## ## Italian Sarcoma Group ## ## ##

  • Cell Therapy
  • Clinical Trial
  • Monoclonal Antibody
  • World
  • Product Initiative